226 related articles for article (PubMed ID: 31750553)
1. Evolution of anosognosia in alzheimer's disease and its relationship to amyloid.
Hanseeuw BJ; Scott MR; Sikkes SAM; Properzi M; Gatchel JR; Salmon E; Marshall GA; Vannini P;
Ann Neurol; 2020 Feb; 87(2):267-280. PubMed ID: 31750553
[TBL] [Abstract][Full Text] [Related]
2. Memory self-awareness in the preclinical and prodromal stages of Alzheimer's disease.
Vannini P; Amariglio R; Hanseeuw B; Johnson KA; McLaren DG; Chhatwal J; Pascual-Leone A; Rentz D; Sperling RA
Neuropsychologia; 2017 May; 99():343-349. PubMed ID: 28385579
[TBL] [Abstract][Full Text] [Related]
3. Anosognosia Is an Independent Predictor of Conversion From Mild Cognitive Impairment to Alzheimer's Disease and Is Associated With Reduced Brain Metabolism.
Gerretsen P; Chung JK; Shah P; Plitman E; Iwata Y; Caravaggio F; Nakajima S; Pollock BG; Graff-Guerrero A;
J Clin Psychiatry; 2017; 78(9):e1187-e1196. PubMed ID: 29022655
[TBL] [Abstract][Full Text] [Related]
4. [Awareness of deficits and anosognosia in Alzheimer's disease].
Antoine C; Antoine P; Guermonprez P; Frigard B
Encephale; 2004; 30(6):570-7. PubMed ID: 15738860
[TBL] [Abstract][Full Text] [Related]
5. Trajectory of Unawareness of Memory Decline in Individuals With Autosomal Dominant Alzheimer Disease.
Vannini P; Hanseeuw BJ; Gatchel JR; Sikkes SAM; Alzate D; Zuluaga Y; Moreno S; Mendez L; Baena A; Ospina-Lopera P; Tirado V; Henao E; Acosta-Baena N; Giraldo M; Lopera F; Quiroz YT
JAMA Netw Open; 2020 Dec; 3(12):e2027472. PubMed ID: 33263761
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Awareness of and Concern About Memory Performance on the Prediction of Progression From Mild Cognitive Impairment to Alzheimer Disease Dementia.
Munro CE; Donovan NJ; Amariglio RE; Papp KV; Marshall GA; Rentz DM; Pascual-Leone A; Sperling RA; Locascio JJ; Vannini P
Am J Geriatr Psychiatry; 2018 Aug; 26(8):896-904. PubMed ID: 29866588
[TBL] [Abstract][Full Text] [Related]
7. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
8. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
[TBL] [Abstract][Full Text] [Related]
9. Aβ and cognitive change: examining the preclinical and prodromal stages of Alzheimer's disease.
Lim YY; Maruff P; Pietrzak RH; Ellis KA; Darby D; Ames D; Harrington K; Martins RN; Masters CL; Szoeke C; Savage G; Villemagne VL; Rowe CC;
Alzheimers Dement; 2014 Nov; 10(6):743-751.e1. PubMed ID: 24589436
[TBL] [Abstract][Full Text] [Related]
10. Anosognosia for memory deficits in mild cognitive impairment: Insight into the neural mechanism using functional and molecular imaging.
Vannini P; Hanseeuw B; Munro CE; Amariglio RE; Marshall GA; Rentz DM; Pascual-Leone A; Johnson KA; Sperling RA
Neuroimage Clin; 2017; 15():408-414. PubMed ID: 28616381
[TBL] [Abstract][Full Text] [Related]
11. Cognitive and functional neuroimaging correlate for anosognosia in mild cognitive impairment and Alzheimer's disease.
Vogel A; Hasselbalch SG; Gade A; Ziebell M; Waldemar G
Int J Geriatr Psychiatry; 2005 Mar; 20(3):238-46. PubMed ID: 15717342
[TBL] [Abstract][Full Text] [Related]
12. Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease.
Edmonds EC; Bangen KJ; Delano-Wood L; Nation DA; Furst AJ; Salmon DP; Bondi MW;
J Int Neuropsychol Soc; 2016 Nov; 22(10):978-990. PubMed ID: 27903335
[TBL] [Abstract][Full Text] [Related]
13. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ;
Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606
[TBL] [Abstract][Full Text] [Related]
14. Cognitive consequences of high Aβ amyloid in mild cognitive impairment and healthy older adults: implications for early detection of Alzheimer's disease.
Lim YY; Ellis KA; Harrington K; Kamer A; Pietrzak RH; Bush AI; Darby D; Martins RN; Masters CL; Rowe CC; Savage G; Szoeke C; Villemagne VL; Ames D; Maruff P;
Neuropsychology; 2013 May; 27(3):322-332. PubMed ID: 23688214
[TBL] [Abstract][Full Text] [Related]
15. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.
Villemagne VL; Burnham S; Bourgeat P; Brown B; Ellis KA; Salvado O; Szoeke C; Macaulay SL; Martins R; Maruff P; Ames D; Rowe CC; Masters CL;
Lancet Neurol; 2013 Apr; 12(4):357-67. PubMed ID: 23477989
[TBL] [Abstract][Full Text] [Related]
16. Amyloid-β, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study.
Pietrzak RH; Lim YY; Neumeister A; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Restrepo C; Martins RN; Masters CL; Villemagne VL; Rowe CC; Maruff P;
JAMA Psychiatry; 2015 Mar; 72(3):284-91. PubMed ID: 25629787
[TBL] [Abstract][Full Text] [Related]
17. Inter-network connectivity and amyloid-beta linked to cognitive decline in preclinical Alzheimer's disease: a longitudinal cohort study.
Van Hooren RWE; Riphagen JM; Jacobs HIL;
Alzheimers Res Ther; 2018 Aug; 10(1):88. PubMed ID: 30153858
[TBL] [Abstract][Full Text] [Related]
18. Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study.
Doraiswamy PM; Sperling RA; Johnson K; Reiman EM; Wong TZ; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Joshi AD; Lu M; Grundman M; Mintun MA; Skovronsky DM; Pontecorvo MJ; ;
Mol Psychiatry; 2014 Sep; 19(9):1044-51. PubMed ID: 24614494
[TBL] [Abstract][Full Text] [Related]
19. Episodic Memory and Learning Dysfunction Over an 18-Month Period in Preclinical and Prodromal Alzheimer's Disease.
Baker JE; Lim YY; Jaeger J; Ames D; Lautenschlager NT; Robertson J; Pietrzak RH; Snyder PJ; Villemagne VL; Rowe CC; Masters CL; Maruff P
J Alzheimers Dis; 2018; 65(3):977-988. PubMed ID: 30103330
[TBL] [Abstract][Full Text] [Related]
20. Primary and secondary anosognosia for memory impairment in patients with Alzheimer's disease.
Hannesdottir K; Morris RG
Cortex; 2007 Oct; 43(7):1020-30. PubMed ID: 17941357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
